The nation’s current drastic increase of pharmaceutical recalls has resulted in a new bill being put into action by the Senate, one that will allow the Food and Drug Administration (FDA) to have more control over drug companies and the drugs they are manufacturing.

While the FDA has some power concerning the drugs that are being sold, many recalls have seemed to slip through. The agency simply lacks authority where pharmaceutical companies are concerned. The new bill will provide the FDA with the funds needed to adequately protect the people, and it will ensure that all drugs that are being manufactured globally pass all safety inspections before being marketed in the United States.

Will the Bill Pass?

The Hill political publication reports that a poll showed 89 percent of Americans will support the bill and congressional action to increase the nation’s drug safety protections. The poll also indicated that 58 percent of consumers said that they “strongly support” this action.

However, those working for pharmaceutical companies say they are not sure if the bill will pass or not. They claim that firmer rules and regulations are not necessary, and that the United States has one of the best and safest systems in the world for testing drugs and protecting patient and consumer safety. That argument seems to fail when we look at Europe’s history of taking dangerous drugs off the market well before the FDA, as happened in the recent Meridia recall.

About the New System

The new bill would update the FDA’s data systems in order to locate all global manufacturers that provide America with drugs. It would also force these companies to document every source that contributes to their products. This will ensure that, in the event of a recall or defective product, all locations and parties involved will be readily available to contact. The bill will also grant the FDA subpoena authority when the need arises to conduct investigations. The FDA enforcement of drug safety has been hindered by underfunding as well as legal restrictions, limitations that the bill would eliminate.

Most importantly, FDA officials only have authority to recall drugs in the medical industry. They do not have such power over pharmaceutical drugs. This bill would allow the FDA to recall drugs prescribed at pharmacies and given to patients in hospitals.

Statistics

According to The Hill, “Last year…the country saw a record 1,742 drug recalls…a 400 percent jump over 2008….80 percent of the active ingredients in the nation’s pharmaceuticals are made abroad, where safety regulations are often much less stringent than U.S. guidelines.” While this outsourcing to other countries is designed to benefit shareholders, oftentimes the quality of the product may be sacrificed in order to cut the cost of making the drug.

Contact Us

Have you or someone you love been affected by a pharmaceutical recall? If so, contact us. Our caring, experienced attorneys are available to provide you with a free consultation and review of your case.

Free Case Evaluation

More About CSS

Other Dangerous Drugs News

  • Researchers in a lab conducting various tests.
    Published On: March 13, 2026

    Research suggests Dupixent (dupilumab) may be linked to an increased risk of cutaneous T-cell lymphoma (CTCL). Learn what studies show, how CTCL may be misdiagnosed as eczema, and the legal options for patients diagnosed with lymphoma after taking Dupixent.

  • Gavel, scales of justice on files on a table signifying a lawsuit being filed.
    Published On: December 26, 2025

    Childers, Schlueter & Smith has filed the first Dupixent lawsuit in Georgia, alleging a link between the eczema drug and cutaneous T-cell lymphoma (CTCL). The complaint highlights questions about risk disclosure.

  • Doctor working on virtual touch screen presses abbreviation: FDA. Food and Drug Administration ( FDA ) Department Service Medical Concept.
    Published On: December 23, 2025

    A recent FDA-approved label change now warns of brain meningioma risks linked to Depo-Provera. This update explains what changed, why lawsuits are being filed, and what the warning may mean for women diagnosed with brain tumors.

  • male patient at dentist office getting anesthesia injection
    Published On: February 6, 2025

    While Suboxone helps fight opioid addiction, it’s now at the center of a growing legal battle over severe, preventable dental harm not disclosed to patients for years.

  • A lawyer present a woman with legal paperwork
    Published On: January 24, 2025

    Women across the U.S. are filing lawsuits against Pfizer after a major study linked long-term use of Depo-Provera to a fivefold increase in the risk of developing brain tumors known as meningiomas.

  • closeup of a young woman getting a depo-provera birth control injection from a doctor with a syringe.
    Published On: October 29, 2024

    Women diagnosed with meningiomas after using Depo-Provera may be eligible for financial compensation, as lawsuits claim Pfizer failed to warn about the potential risk of brain tumors.